Literature DB >> 28066790

Resistant Hypertension and Sleep Duration among Blacks with Metabolic Syndrome MetSO.

April Rogers1, Olivia Necola2, Azizi Sexias1, Alla Luka3, Valerie Newsome1, Stephen Williams1, Samy I McFarlane3, Girardin Jean-Louis1.   

Abstract

INTRODUCTION: Resistant hypertension (RHTN) is an important condition affecting 29% of the hypertensive population in the U.S., especially among blacks. Sleep disturbances, like obstructive sleep apnea, insomnia, and short sleep duration, are increasingly recognized as underlying modifiable factors for RHTN. We evaluated associations of RHTN with short sleep duration among blacks with metabolic syndrome.
METHODS: Data from the Metabolic Syndrome Outcome Study (MetSO), a NIH-funded cohort study characterizing metabolic syndrome (MetS) among blacks were analyzed. MetS was defined according to criteria from the Adult Treatment Panel (ATP III). RHTN was defined according to guidelines from the American Heart Association. Short sleep was defined as self-reported sleep duration <7 hrs experienced during a 24-hour period.
RESULTS: Analysis was based on 1,035 patients (mean age: 62±14years; female: 69.2%). Of the sample, 90.4% were overweight /obese; 61.4% had diabetes; 74.8% had dyslipidemia; 30.2% had a history of heart disease; and 48% were at high risk for obstructive sleep apnea. Overall, 92.6% reported physician-diagnosed hypertension (HTN) and 20.8% met criteria for RHTN. Analyses showed those with RHTN were more likely to be short sleepers (26.8% vs. 14.9%, p< 0.001). Based on logistic regression analysis, adjusting for effects of age, sex, and medical comorbidities, patients with metabolic syndrome and RHTN had increased odds of being short sleepers (OR = 1.95, 95% CI: 1.28-2.97, p = 0.002).
CONCLUSION: Among blacks with metabolic syndrome, patients meeting criteria for resistant hypertension showed a twofold greater likelihood of being short sleepers, prompting the need for sleep screening in this vulnerable population.

Entities:  

Keywords:  Metabolic syndrome; Resistant hypertension; Sleep duration

Year:  2016        PMID: 28066790      PMCID: PMC5214926          DOI: 10.4172/2325-9639.1000183

Source DB:  PubMed          Journal:  J Sleep Disord Treat Care        ISSN: 2325-9639


  19 in total

Review 1.  Resistant hypertension and sleep apnea: pathophysiologic insights and strategic management.

Authors:  Stephen K Williams; Joseph Ravenell; Girardin Jean-Louis; Ferdinand Zizi; James A Underberg; Samy I McFarlane; Gbenga Ogedegbe
Journal:  Curr Diab Rep       Date:  2011-02       Impact factor: 4.810

Review 2.  Obstructive sleep apnea and cardiovascular disease: role of the metabolic syndrome and its components.

Authors:  Girardin Jean-Louis; Ferdinand Zizi; Luther T Clark; Clinton D Brown; Samy I McFarlane
Journal:  J Clin Sleep Med       Date:  2008-06-15       Impact factor: 4.062

3.  Obstructive sleep apnea and cardiovascular disease: evidence and underlying mechanisms.

Authors:  G Jean-Louis; F Zizi; Db Brown; G Ogedegbe; Js Borer; Si McFarlane
Journal:  Minerva Pneumol       Date:  2009-12

Review 4.  Resistant hypertension, obstructive sleep apnoea and aldosterone.

Authors:  T Dudenbostel; D A Calhoun
Journal:  J Hum Hypertens       Date:  2011-06-09       Impact factor: 3.012

5.  Positive effect of CPAP treatment on the control of difficult-to-treat hypertension.

Authors:  M A Martínez-García; R Gómez-Aldaraví; J-J Soler-Cataluña; T G Martínez; B Bernácer-Alpera; P Román-Sánchez
Journal:  Eur Respir J       Date:  2007-02-14       Impact factor: 16.671

6.  Self-reported sleep quality is associated with the metabolic syndrome.

Authors:  J Richard Jennings; Matthew F Muldoon; Martica Hall; Daniel J Buysse; Stephen B Manuck
Journal:  Sleep       Date:  2007-02       Impact factor: 5.849

Review 7.  Detection, evaluation, and treatment of severe and resistant hypertension: proceedings from an American Society of Hypertension Interactive forum held in Bethesda, MD, U.S.A., October 10th 2013.

Authors:  William B White; J Rick Turner; Domenic A Sica; John D Bisognano; David A Calhoun; Raymond R Townsend; Herbert D Aronow; Deepak L Bhatt; George L Bakris
Journal:  J Am Soc Hypertens       Date:  2014-07-15

8.  Independent association of drug-resistant hypertension to reduced sleep duration and efficiency.

Authors:  Oded Friedman; T Douglas Bradley; Pimon Ruttanaumpawan; Alexander G Logan
Journal:  Am J Hypertens       Date:  2009-11-19       Impact factor: 2.689

9.  Resistant hypertension: diagnosis, evaluation, and treatment. A scientific statement from the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research.

Authors:  David A Calhoun; Daniel Jones; Stephen Textor; David C Goff; Timothy P Murphy; Robert D Toto; Anthony White; William C Cushman; William White; Domenic Sica; Keith Ferdinand; Thomas D Giles; Bonita Falkner; Robert M Carey
Journal:  Hypertension       Date:  2008-04-07       Impact factor: 10.190

10.  Resistant hypertension and obstructive sleep apnea in the primary-care setting.

Authors:  M Demede; A Pandey; F Zizi; R Bachmann; M Donat; S I McFarlane; G Jean-Louis; G Ogedegbe
Journal:  Int J Hypertens       Date:  2011-06-08       Impact factor: 2.420

View more
  3 in total

Review 1.  Disparities in Hypertension Among African-Americans: Implications of Insufficient Sleep.

Authors:  Naima Covassin; Eddie L Greene; Prachi Singh; Virend K Somers
Journal:  Curr Hypertens Rep       Date:  2018-06-08       Impact factor: 5.369

Review 2.  Sleep Duration and Blood Pressure: Recent Advances and Future Directions.

Authors:  Nour Makarem; Ari Shechter; Mercedes R Carnethon; Janet M Mullington; Martica H Hall; Marwah Abdalla
Journal:  Curr Hypertens Rep       Date:  2019-04-05       Impact factor: 5.369

Review 3.  Resistant Hypertension Management: Comparison of the 2017 American and 2018 European High Blood Pressure Guidelines.

Authors:  Guido Grassi; David A Calhoun; Giuseppe Mancia; Robert M Carey
Journal:  Curr Hypertens Rep       Date:  2019-07-18       Impact factor: 5.369

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.